NRx Pharmaceuticals (NASDAQ: NRXP) was featured in a recent article that discussed its approach to bring preservative-free ketamine-based therapies to market, pursuing distinct regulatory and ...

OXFORD, England--(BUSINESS WIRE)--Beckley Psytech Ltd, a private, clinical-stage biotechnology company developing rapid-acting, short-duration psychedelic medicines for neuropsychiatric conditions, ...

MUNICH, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today favorable results from its ...

Mindbio Therapeutics Corp. ( ($TSE:MBIO) ) just unveiled an announcement. MindBio Therapeutics has successfully completed dosing in its landmark ...

Compass Pathways plc is poised to start the first ever phase III trial of the psychedelic drug psilocybin, after getting U.S. FDA backing for a study in treatment-resistant depression. The phase III, ...

The FDA designation expands the drug’s potential patient pool tenfold, to an estimated 13 million Americans who consider suicide annually. Clinical trials demonstrated rapid and statistically ...

Compass Pathways Plc (($CMPS)) announced an update on their ongoing clinical study. Compass Pathways Plc is conducting a Phase III clinical study ...